Top Markets
Coin of the day
Climb Bio, Inc. Climb Bio, Inc.

Climb Bio, Inc.

CLYM
Rangering i aksjer #10440
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic... Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
Aksjekurs
$14.66
Sist synkronisert: 2026-08-28
Markedsverdi
$839.37M
Endring (1 dag)
-2.67%
Endring (1 år)
557.32%
Land
US
Handel Climb Bio, Inc. (CLYM)

Kategori

P/S-forhold for Climb Bio, Inc. (CLYM)
P/S-forhold per 2026 TTM: 0
Ifølge Climb Bio, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for Climb Bio, Inc. fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
10.17 -
US
10.13 -
NL
2.95 -
AU
11.28 -
US
- -
CH